Many companies have already published their figures for the third quarter. However, not all of them yet. This week, the US fintech company Marqeta will reveal its results. The group is active in a growth market and counts well-known companies such as Square or Coinbase among its customers. However, currently, the risks could be greater than the opportunities.
Marqeta is a payment service provider that also issues white-label credit cards. Companies can also create customized virtual cards online for their customers and add the desired bonus system at the same time. As cash continues to retreat and e-commerce booms at the same time, there are great opportunities for companies in the payment sector. At the same time, Marqeta is constantly entering into new collaborations, such as the most recent one with Coinbase.
If you want to find more details about the US fintech company Marqeta and its recent collaborations, download for free our companion app. The Born2Invest business news mobile app is available for free for both Android and iOS devices and keeps its readers up to date with the latest market updates.
Well-known players acquired
After the IPO at the beginning of June at $27.00, Marqeta’s shares slid, but at the end of October, the price reached a new all-time high of $43.8. What happened? Among other things, the company is now cooperating with Coinbase. In the process, Marqeta issues Visa debit cards for Coinbase, customers can also load them with cryptocurrencies and use them in payment transactions. They are also working more closely with Uber and Bill.com.
Beware of numbers
On Wednesday, November 10th, Marqeta will now publish its Q3 figures. It will probably be difficult to compare them with the same quarter last year, as this was certainly an exceptional period due to the pandemic. The main customer Square already weakened during the presentation of the figures and missed the forecast for revenues. The consensus expected revenue growth of 42 percent for Marqeta.
In the long term, the opportunities for Marqeta remain high, but a new entry before the figures is not urgent. Investors stay with it and note the stop at $18.00. All others wait and see, because due to the high valuation, the share is particularly sensitive to deviations of the figures from the consensus. Since growth at important customers and competitors has already weakened, the risk that Marqeta will also be affected is high.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in DER AKTIONAER, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
Boiron Enters the Medical Cannabis Business
Boiron is counting on cannabis to restore his health. The change was announced on the BFM Business TV channel. It's...
Tech Innovation Is about to Takeoff: Get Ready for It with XRApplied
While most of us grew up bearing witness to a tremendous pace of tech advancements, things seem to have stagnated...
Glen Invest, the Moroccan Investment Company Set Up in Casablanca
Glen Invest's priorities for the region are clear. They concern investments in the processing industry for mass consumer goods, "with...
Why Are Syncrude, Ledcor Group, and Ekati Mines So Excited about Triad Pro Innovators’ New EEL Diesel Hybrid Genset?
It's understandable if the words ‘diesel hybrid genset' don’t get your heart racing. But what if we throw in an...
New Strategy, New Brand: The Secret Re-Start of Exporo
According to information of Finanz-Szene.de, the strategy turn and the internal reorganization are also a consequence of difficulties, which Exporo...
Crypto2 weeks ago
Satispay and Young Platform Team Up to Simplify Cryptocurrency Purchases
Biotech2 weeks ago
Rethinking DMT: Algernon Pharmaceuticals’ Novel Approach to Stroke Treatment
Business2 weeks ago
Before the Metaverse: Augmented Reality in Education
Featured2 weeks ago
Why Soybeans and Soybean Oil Closed Lower